We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-7.6%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$5.27B
AUM Growth
-$1.19B
Cap. Flow
-$465M
Cap. Flow %
-8.83%
Top 10 Hldgs %
38.7%
Holding
148
New
20
Increased
18
Reduced
35
Closed
32

Top Buys

Rank Stock Value
1
SWTX
SpringWorks Therapeutics
SWTX
+$175M
2
HUM icon
Humana
HUM
+$51M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$50.2M
4
BLU
BELLUS Health Inc.
BLU
+$49.6M
5
RARE icon
Ultragenyx Pharmaceutical
RARE
+$41M

Top Sells

Rank Stock Value
1
A icon
Agilent Technologies
A
+$66.7M
2
BSX icon
Boston Scientific
BSX
+$62.9M
3
BMY icon
Bristol-Myers Squibb
BMY
+$61M
4
MRK icon
Merck
MRK
+$51.7M
5
ILMN icon
Illumina
ILMN
+$51.6M

Sector Composition

Rank Sector Weight
1 Healthcare 97.14%
2 Financials 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ACAD icon
101
Acadia Pharmaceuticals
ACAD
$4.46B
$3.46M 0.07%
96,143
-5,757
-6% -$175K
AMRN
102
Amarin Corp
AMRN
$297M
$3.35M 0.06%
11,055
-24,825
-69% -$8.66M
MRSN
103
DELISTED
Mersana Therapeutics
MRSN
$2.99M 0.06%
75,645
– –
VYNE icon
104
VYNE Therapeutics
VYNE
$2.97M 0.06%
184
-3
-2% -$48.4K
CRIS icon
105
Curis
CRIS
$9.76M
$2.78M 0.05%
+3,104
New +$2.63M
ICPT
106
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$2.14M 0.04%
+32,200
New +$2.16M
ADAP
107
DELISTED
Adaptimmune Therapeutics
ADAP
$2.04M 0.04%
1,350,655
– –
ELDN icon
108
Eledon Pharmaceuticals
ELDN
$259M
$1.97M 0.04%
176,851
– –
PBYI icon
109
CALL
Puma Biotechnology
PBYI
$397M
$1.61M 0.03%
+150,000
New +$1.62M
SNDX icon
110
Syndax Pharmaceuticals
SNDX
$1.68B
$1.58M 0.03%
212,000
– –
SPRO icon
111
Spero Therapeutics
SPRO
$68.3M
$1.49M 0.03%
140,709
-366,762
-72% -$3.86M
CVM icon
112
PUT
CEL-SCI Corp
CVM
$20.3M
$1.12M 0.02%
+4,167
New +$977K
RUBY
113
PUT
DELISTED
Rubius Therapeutics, Inc
RUBY
$785K 0.01%
+100,000
New +$1.17M
KALV
114
DELISTED
KalVista Pharmaceuticals
KALV
$449K 0.01%
+38,733
New +$626K
BLRX
115
BioLineRX
BLRX
$12.3M
$183K ﹤0.01%
1,731
– –
XYLO
116
DELISTED
Xylo Technologies
XYLO
$26K ﹤0.01%
375
– –
A icon
117
Agilent Technologies
A
$39.4B
– –
-893,200
Closed -$66.7M
ABBV icon
118
CALL
AbbVie
ABBV
$471B
– –
-200,000
Closed -$14.5M
ADPT icon
119
Adaptive Biotechnologies
ADPT
$3.49B
– –
-120,000
Closed -$5.8M
APLS
120
CALL
DELISTED
Apellis Pharmaceuticals
APLS
– –
-75,000
Closed -$1.9M
ASMB icon
121
Assembly Biosciences
ASMB
$493M
– –
-43,633
Closed -$7.06M
BMRN icon
122
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-75,000
Closed -$6.42M
BMRN icon
123
PUT
BioMarin Pharmaceuticals
BMRN
$11.9B
– –
-75,000
Closed -$6.42M
BMY icon
124
CALL
Bristol-Myers Squibb
BMY
$130B
– –
-500,000
Closed -$22.7M
BMY icon
125
Bristol-Myers Squibb
BMY
$130B
– –
-1,345,200
Closed -$61M
2 3 4
5
6

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
SGM
Skye Global Management West Palm Beach, Florida $5B AUM 11.9% 1-Year Est. Return

OrbiMed's Q3 2019 Portfolio in Review

As of Q3 2019, OrbiMed held 148 positions worth $5.27B, down 18% from $6.46B the previous quarter. Its ten largest holdings account for 39% of the portfolio.

OrbiMed withdrew a net $465M in Q3 2019, closing 32 positions and reducing 35 holdings. Its most notable exit was Agilent Technologies, an estimated $66.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 96% a quarter earlier, followed by Financials.

Against the trend, OrbiMed opened a new position in SpringWorks Therapeutics worth $161M.

  • OrbiMed's largest Q3 2019 buy was SpringWorks Therapeutics: 7,406,307 shares worth $161M.
  • OrbiMed added most to Ultragenyx Pharmaceutical in Q3 2019, an estimated $41M increase.
  • OrbiMed's biggest Q3 2019 reduction was Boston Scientific, cutting an estimated $62.9M.
  • OrbiMed fully exited Agilent Technologies in Q3 2019, selling an estimated $66.7M.
  • OrbiMed's ten largest holdings make up 39% of its $5.27B portfolio in Q3 2019.
  • OrbiMed opened 20 new positions and closed 32 in Q3 2019.
  • OrbiMed's portfolio value fell 18% quarter-over-quarter to $5.27B.

Based on OrbiMed's 13F filing for Q3 2019, filed 14 Nov 2019.